Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $2.9852W HIGH $10.99
Volume
2.55 M
Value Traded
3.35 M
Short % Float
29.86%
-9.07%Week
-28.35%1 Month
-33.4%3 Month
-46.32%6 Month
-46.21%5 Year
-46.21%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
263.37 M
EPS (TTM)
-1.06
P/E Ratio
-
Ent. Value
29.20 M
Total Shares
82.05 M
Float Shares
69.09 M
Insiders
15.83%
Institutions
99.74%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
LXEO Catalyst Timeline
Dated clinical, regulatory and corporate events for Lexeo Therapeutics, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Lexeo Therapeutics, Inc.
274Total events
17Upcoming
68Tier-1 (high impact)
2020 to 2028Coverage
Upcoming catalysts 2
Event history 50
▲Partnership / LicenseCorporate
Apertura to provide Lexeo access to TfR1 CapX for Friedreich ataxia program
Friedreich ataxiasource ↗
▲RMATLX2020Designation
FDA granted RMAT designation to LX2020
PKP2-associated arrhythmogenic cardiomyopathy (PKP2-ACM)source ↗
▲Interim Efficacy DataLX2020Clinical Data
Interim clinical data from HEROIC-PKP2 trial
PKP2-associated arrhythmogenic cardiomyopathy (PKP2-ACM)source ↗
▲PublicationLX2006FiledPresentation
Phase I/II data for LX2006 published in JAMA Cardiology
Friedreich ataxiasource ↗
▲Accelerated Approval PathwayLX2006FiledDesignation
FDA confirmed accelerated approval pathway for LX2006
Friedreich ataxia cardiomyopathysource ↗
▲FDA Feedback ReceivedLX2006FiledFDA Meeting
FDA feedback incorporated into SUNRISE-FA 2 design; no additional nonclinical bridging studies required
Friedreich ataxia cardiomyopathysource ↗
◆Enrollment UpdateLX2006FiledTrial
CLARITY-FA natural history study enrollment ongoing and progressing well
Friedreich ataxia cardiomyopathysource ↗
▲Trial InitiationLX2006FiledTrial
First patient enrolled in pivotal SUNRISE-FA 2 study
Friedreich ataxiasource ↗
◆First Patient DosedLX2006FiledTrial
First patient expected to be enrolled by end of June 2026
Friedreich ataxia cardiomyopathysource ↗
●Oral PresentationPresentation
Participation in 2026 RBC Capital Markets Global Healthcare Conference fireside chat
◆Oral PresentationPresentation
Oral presentation: Demonstrated Comparability Between Adherent HEK293 and Sf9 Baculovirus Suspension AAVrh.10 Clinical Manufacturing Process
AAV manufacturingsource ↗
◆Poster PresentationPresentation
Poster presentation: Scale-Up and Manufacturing Comparability of an Sf RVN Baculovirus Production Process from 10 L to 200 L for AAV
AAV manufacturingsource ↗
◆Oral PresentationLX2006FiledPresentation
Oral presentation: Gene Therapy for Friedreich Ataxia Cardiomyopathy: Safety and Preliminary Assessment of Efficacy
Friedreich ataxia cardiomyopathysource ↗
◆Poster PresentationLX2006FiledPresentation
Poster presentation: Gene Therapy for the Neurologic Manifestations of Friedreich’s Ataxia by Delivery of Therapeutic AAV Vectors to the Cerebellum
Friedreich ataxia neurologic manifestationssource ↗
◆Oral PresentationPresentation
Oral presentation: A Gene Therapy Approach for the Treatment of TNNI3 Cardiomyopathy
TNNI3 cardiomyopathysource ↗
◆Oral PresentationLX2006FiledPresentation
Multiple presentations on LX2006 at ASGCT 2026
Friedreich Ataxiasource ↗
▲Interim AnalysisLX2006FiledTrial
Phase I/II interim clinical data of LX2006 showing sustained improvements
Friedreich Ataxiasource ↗
▲Preclinical PoCLX2006FiledPreclinical
Nonhuman primate research with LX2006 demonstrating sequential dosing potential
Friedreich Ataxiasource ↗
▲Manufacturing MilestoneLX2006FiledCMC / Inspection
CMC comparability data for LX2006 between HEK293 and Sf9 processes
Friedreich Ataxiasource ↗
▲Preclinical PoCLX2022Preclinical
Preclinical data for LX2022 demonstrating proof-of-concept in porcine model
Hypertrophic Cardiomyopathy (TNNI3)source ↗
◆Trial InitiationLX2006FiledTrial
SUNRISE-FA 2 pivotal trial initiation on track for Q2 2026
Friedreich ataxia cardiomyopathysource ↗
◆FDA Feedback ReceivedLX2006FiledFDA Meeting
Awaiting final FDA feedback on SUNRISE-FA 2 protocol submission
Friedreich Ataxiasource ↗
▲Manufacturing MilestoneLX2006FiledCMC / Inspection
First CMC Development and Readiness Program (CDRP) meeting with FDA for LX2006
Friedreich Ataxiasource ↗
◆Oral PresentationLX2006FiledPresentation
Late-breaking oral presentation at ACC Annual Meeting for LX2006
Friedreich Ataxiasource ↗
◆Oral PresentationLX2020Presentation
Late-breaking oral presentation at ACC Annual Meeting for LX2020
PKP2 Arrhythmogenic Cardiomyopathysource ↗
▲Partnership / LicenseCorporate
Research collaboration with Johnson & Johnson to explore targeted cardiac delivery of AAV gene therapy
◆Oral PresentationPresentation
Oppenheimer 36th Annual Healthcare Life Sciences Conference Fireside Chat
◆Oral PresentationPresentation
Guggenheim Emerging Outlook: Biotech Summit 2026 Fireside Chat
●NDA SubmissionLX2006FiledRegulatory Filing
Submitted final registrational trial design and SAP for SUNRISE-FA 2 to FDA
Friedreich Ataxiasource ↗
▲Partnership / LicenseCorporate
Update on strategic partnership with Perceptive Xontogeny Venture Funds and venBio Partners for cardiac RNA therapeutics
genetic cardiac diseasessource ↗
◆Oral PresentationPresentation
Lexeo Therapeutics to present at 44th Annual J.P. Morgan Healthcare Conference
▲Topline ReadoutLX2020Clinical Data
Interim Phase I/II data for LX2020 announced
PKP2-associated arrhythmogenic cardiomyopathysource ↗
●Oral PresentationLX2020Presentation
Company webcast to discuss interim data
PKP2-associated arrhythmogenic cardiomyopathysource ↗
▲Partnership / LicenseCorporate
Research collaboration with Johnson & Johnson to explore localized cardiac delivery of AAV gene therapy using Impella heart pumps
cardiovascular diseasessource ↗
◆Trial InitiationLX2006FiledTrial
Expected initiation of registrational study for LX2006
Friedreich ataxiasource ↗
◆Additional DataLX2020Clinical Data
Additional clinical data from high-dose cohorts expected
PKP2 arrhythmogenic cardiomyopathysource ↗
▲Interim AnalysisLX2020Trial
Positive interim clinical data from HEROIC-PKP2 Phase I/II trial
PKP2 Arrhythmogenic Cardiomyopathysource ↗
Past FDA Catalysts and PDUFA Decisions
How LXEO actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-10-07 | Intravenous AAVrh.10hFXN (LX2006) | Phase 1 and 2 data presentation | Phase 1 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D35 / 100
Pipeline Score
$25M
Pipeline Value
Richly Valued
Valuation Signal
1
Drugs Scored
0.1x
rNPV / MCap
Top 54%
Micro Cap(rank 356 of 658)
Percentile Rank
Lexeo Therapeutics, Inc. faces pipeline headwinds (35/100), with $100M risk-adjusted pipeline value, led by LX1001 in Alzheimer Disease (Phase 1).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| LX1001 Monoclonal antibodyNCT05400330 | Alzheimer Disease | Phase 1 | ACTIVE NOT_RECRUITING | 25 | Nov 1, 2028 |
Clinical Trial Results
Readouts, endpoints and source filings for every LXEO program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| LX2006 BreakthroughFast TrackAccelerated+3 | Friedreich ataxia | Phase 1/2 | 2026-10-01 | early stabilization or improvement in mFARS scores among LX2006-treated participants compared with propensity-matched control cohortRead More | Lexeo Therapeutics Announces Oral Presentation of LX2006 at the International Congress of Parkinson’s Disease and Movement Disorders 2026 (MDS)Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Tamayo Louis EdwardOfficer (Chief Financial Officer) | Sell | -4,117 92,907 held | $4.91 | 08/18/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in LXEO
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| AFFINITY ASSET ADVISORS, LLC | 1.2 % (-20 %) | 27.03 M | 5.81 M | 15% ( 757.40 K) |
LXEO Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How LXEO ranks across every disease it competes in
Competitive Position is a premium feature
See how LXEO ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialLXEO News
LXEO▼ -3%today
Lexeo Therapeutics to Participate in the Chardan Healthcare Conference
Lexeo Therapeutics will participate in the Chardan Healthcare Conference on October 20, 2026. The event will feature a fireside chat and will be available for live streaming on the company's website. Lexeo is dedicated to advancing treatments for genetic diseases, particularly in cardiovascular and neurological areas.
Read more →LXEO▲ +7.1%on this news
Lexeo Therapeutics Announces Oral Presentation of LX2006 at the International Congress of Parkinson’s Disease and Movement Disorders 2026 (MDS)
Lexeo Therapeutics announced that its abstract for LX2006 has been accepted for an oral presentation at the International Congress of Parkinson’s Disease and Movement Disorders 2026. The presentation will showcase data on neurologic improvements in patients treated with LX2006 and new analyses of mFARS subscores. This highlights the potential of LX2006 in addressing Friedreich ataxia.
Read more →LXEO▼ -13.5%on this news
Apertura Gene Therapy to Provide Lexeo Therapeutics Access to TfR1 CapX™ for Program Designed to Treat Friedreich Ataxia
Apertura Gene Therapy has partnered with Lexeo Therapeutics to provide access to its TfR1 CapX, a next-generation AAV capsid aimed at treating Friedreich ataxia. This capsid is designed to cross the blood-brain barrier and may offer new treatment avenues for this genetic disorder. The collaboration is expected to enhance Lexeo's research efforts in addressing the significant unmet needs of Friedreich ataxia patients.
Read more →LXEO▼ -13.5%on this newsshared move
Lexeo Therapeutics to Participate in the Stifel 2026 Virtual Cardiometabolic Forum
Lexeo Therapeutics will participate in the Stifel 2026 Virtual Cardiometabolic Forum on September 30, 2026. The event will feature a fireside chat and will be available for live streaming on the company's website. Lexeo is focused on developing therapies for genetic diseases, including Friedreich ataxia and arrhythmogenic cardiomyopathy.
Read more →LXEOLexeo Therapeutics Enters Into Agreement to Acquire Mantle Therapeutics and Announces Multiple New Strategic Collaborations to Expand Leadership in Friedreich Ataxia
Lexeo Therapeutics has announced its acquisition of Mantle Therapeutics to enhance its Friedreich ataxia treatment capabilities. The acquisition includes multiple therapeutic modalities aimed at increasing frataxin levels in the brain. Additionally, Lexeo has initiated three strategic collaborations to support gene therapy advancements. The company's pivotal SUNRISE-FA 2 study remains a priority, with topline data expected in the second half of 2027.
Read more →LXEOLexeo Therapeutics to Participate in Upcoming Investor Conferences in September
Lexeo Therapeutics, a clinical stage genetic medicine company, will participate in two investor conferences in September 2026. The Cantor Global Healthcare Conference will feature a fireside chat on September 9, followed by the Baird 2026 Global Healthcare Conference on September 15. Both events will be webcast live, showcasing the company's commitment to investor engagement.
Read more →LXEOLexeo Therapeutics Reports Second Quarter 2026 Financial Results and Operational Highlights
Lexeo Therapeutics has reported its second quarter 2026 financial results, highlighting key operational milestones. The company has finalized the protocol for the SUNRISE-FA 2 trial and initiated patient enrollment. Topline data for the pivotal study of LX2006 is anticipated in the latter half of 2027.
Read more →LXEOLexeo Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for LX2020 for the Treatment of PKP2 Arrhythmogenic Cardiomyopathy
Lexeo Therapeutics has received FDA Regenerative Medicine Advanced Therapy (RMAT) designation for its gene therapy candidate LX2020, aimed at treating PKP2-associated arrhythmogenic cardiomyopathy (PKP2-ACM). This designation is based on promising interim data from the ongoing HEROIC-PKP2 Phase I/II clinical trial. LX2020 also holds Orphan Drug and Fast Track designations, enhancing its development prospects.
Read more →LXEOLexeo Therapeutics Announces Publication in JAMA Cardiology of Phase I/II Data for LX2006 in Friedreich Ataxia
Lexeo Therapeutics announced the publication of Phase I/II data for LX2006 in Friedreich ataxia in JAMA Cardiology. The results indicate that LX2006 is generally well tolerated and shows early signs of efficacy, with improvements in cardiac and neurologic measures. The pivotal SUNRISE-FA 2 study is set to initiate in Q2 2026, with topline data expected in 2H 2027.
Read more →LXEO▲ +6.4%on this newsshared move
Lexeo Therapeutics Announces Regulatory Update and Registrational Trial Design for LX2006 Gene Therapy in Friedreich Ataxia
Lexeo Therapeutics has announced the finalization of the SUNRISE-FA 2 pivotal trial protocol for its gene therapy candidate LX2006, targeting Friedreich ataxia cardiomyopathy. The trial will enroll participants aged 16 and older and aims for a BLA submission under the accelerated approval pathway in 2028. The study design incorporates FDA feedback and aims to address significant unmet needs in patients with this condition.
Read more →LXEOLexeo Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference
Lexeo Therapeutics, a clinical stage genetic medicine company, will participate in the 2026 RBC Capital Markets Global Healthcare Conference. The event is scheduled for May 19, 2026, at 2:35 p.m. ET in New York. The presentation will be available via live webcast and later as a replay on their website.
Read more →LXEOLexeo Therapeutics Reports First Quarter 2026 Financial Results and Operational Highlights
Lexeo Therapeutics reported its Q1 2026 financial results, highlighting advancements in its clinical pipeline, particularly for LX2006 in Friedreich Ataxia and LX2020 in PKP2 Arrhythmogenic Cardiomyopathy. The company is preparing to initiate the SUNRISE-FA 2 pivotal trial pending FDA feedback. Financially, Lexeo maintains a strong position with $227.6 million in cash, expected to fund operations into 2028.
Read more →LXEOLexeo Therapeutics Announces Multiple Presentations at the 29th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting
Lexeo Therapeutics will present new data at the 29th ASGCT Annual Meeting, showcasing advancements in its cardiac gene therapy programs and AAV manufacturing. Key presentations include a novel TNNI3 gene therapy and updates on the LX2006 candidate for Friedreich ataxia. The event provides an opportunity to demonstrate the company's scientific progress to industry peers.
Read more →LXEOLexeo Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights
Lexeo Therapeutics reported its fourth quarter and full year 2025 financial results, highlighting positive developments in its LX2006 and LX2020 clinical programs. The company has submitted the pivotal trial protocol for LX2006 to the FDA and plans to initiate the SUNRISE-FA 2 trial in the first half of 2026. During the ACC Annual Meeting, promising efficacy and safety results were presented for both programs, underscoring Lexeo's progress in addressing cardiovascular diseases. The company's financials reflect a reduced net loss compared to the previous year alongside a robust cash position to support ongoing operations.
Read more →LXEOLexeo Therapeutics to Participate in the Leerink Global Healthcare Conference
Lexeo Therapeutics, a clinical stage genetic medicine company, will participate in the Leerink Global Healthcare Conference on March 10, 2026. The event will feature a fireside chat and will be webcast live, allowing broader access to stakeholders. Lexeo is dedicated to developing innovative treatments for cardiovascular diseases, including specific therapies for conditions like Friedreich ataxia cardiomyopathy.
Read more →LXEO▼ -5.2%on this news
Lexeo Therapeutics to Participate in Upcoming Investor Conferences in February
Lexeo Therapeutics announced its participation in two investor conferences in February 2026. The company will engage in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit on February 12 and at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26. These events highlight Lexeo's commitment to advancing genetic medicine for cardiovascular diseases.
Read more →LXEOLexeo Therapeutics Announces Key Leadership Appointments Strengthening Cardiovascular Expertise Alongside Updates to Strategic Partnership for Novel Cardiac RNA Therapeutics
Lexeo Therapeutics has announced key leadership appointments, including Dr. Narinder Bhalla as Chief Medical Officer, to bolster its expertise in cardiovascular medicine. The company also updated its strategic partnership with Perceptive Xontogeny and venBio Partners to develop novel RNA therapies for genetic cardiac diseases. These moves aim to enhance Lexeo's clinical and commercial objectives.
Read more →LXEO▼ -23%on this news
Lexeo Therapeutics Announces Positive Interim Phase I/II Data for LX2020 for the Treatment of PKP2-Associated Arrhythmogenic Cardiomyopathy
Lexeo Therapeutics announced promising interim data from its HEROIC-PKP2 Phase I/II clinical trial for LX2020, a treatment for PKP2-associated arrhythmogenic cardiomyopathy. The therapy was well tolerated among ten participants, showing significant increases in PKP2 protein expression, with mean improvements in arrhythmia burden for most participants. Despite some elevated liver function tests and a serious adverse event, the data highlight the potential of LX2020 in addressing the underlying causes of cardiac dysfunction. Lexeo aims to continue advancing LX2020's development and plans regulatory engagement in the coming year.
Read more →LXEO▼ -5.5%on this news· ran to -26% by day 3shared move
Lexeo Therapeutics Announces Research Collaboration to Explore Targeted Cardiac Delivery of AAV Gene Therapy
Lexeo Therapeutics has announced a research collaboration with Johnson & Johnson aimed at exploring localized cardiac delivery methods for adeno associated viral (AAV) gene therapy. This partnership seeks to advance gene therapy for cardiovascular diseases by leveraging Impella heart pump technology to direct delivery to the heart. The goal is to reduce AAV dosage requirements and improve safety while enhancing clinical efficacy. Lexeo is focused on developing innovative treatments for genetic causes of cardiovascular conditions.
Read more →LXEOLexeo Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
Lexeo Therapeutics, a clinical stage genetic medicine company, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026. CEO R. Nolan Townsend will discuss the company's innovative approaches to treating cardiovascular diseases. The event will be available for live streaming and later replay on their website.
Read more →About Lexeo Therapeutics, Inc.
Headquarters345 PARK AVENUE SOUTH, NEW YORK, NY, 10010
BIOPHARMAWATCH ELITE PLUS
Trade the next LXEO catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime